Modified Silica Stationary Phase for Peptide Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current silica particles used in HPLC for purifying high-molecular weight modified conjugated peptides like GLP-1 receptor agonists and GLP-2 analogs face challenges in achieving high selectivity and recovery, often requiring multiple purification steps and struggling with impurity separation, especially due to the peptides' tendency to form aggregates at acidic pH.
Innovation Solution
Development of silica particles with a fine pore size of 1 to 250 Angstroms and modified with silane groups comprising alkyl, aryl, alkylaryl, heteroalkyl, and heteroaryl groups, which are used as a stationary phase in HPLC to enhance separation performance and facilitate efficient purification of these peptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional silica particles are used for HPLC purification of high-molecular weight modified conjugated peptides, then the purification process can be performed, but the selectivity and recovery are insufficient and multiple purification steps are required
Solution Approach 1:
The patent applies parameter changes by modifying the pore size of silica particles to a specific range (5-250 Å, preferably 20-150 Å) and introducing functional groups (carboxyl, sulfonic acid, phosphonic acid, or boronic acid groups) with specific concentration ranges. These parameter modifications enable single-step purification achieving >99.5% purity with >70% recovery, resolving the contradiction between purification selectivity and process complexity.
Solution Approach 2:
The patent creates composite stationary phases by combining silica particles with specific functional groups (carboxyl, sulfonic acid, phosphonic acid, or boronic acid) attached to the silica surface. This composite structure provides both the mechanical stability of silica and the specific chemical interactions needed for high-selectivity single-step purification of conjugated peptides, eliminating the need for multiple purification steps.
2Manufacturing precision
If conventional silica particles are used, then the purification process can proceed, but impurity separation is difficult due to peptide aggregation at acidic pH
Solution Approach 1:
The patent modifies the chemical environment by introducing ionizable functional groups (carboxyl, sulfonic acid, phosphonic acid, or boronic acid) that can alter the local pH and electrostatic environment around the peptide molecules. This prevents peptide aggregation at acidic pH by providing repulsive electrostatic forces or hydrogen bonding interactions, thereby enabling effective impurity separation that was previously hindered by aggregation.
Solution Approach 2:
The functional groups attached to silica particles act as intermediaries between the stationary phase and the peptide molecules. These groups (carboxyl, sulfonic acid, phosphonic acid, or boronic acid) mediate the interaction by providing specific chemical functionalities that prevent aggregation and enhance selective binding, allowing impurity separation to proceed effectively even under acidic conditions where aggregation would normally occur.
3Manufacturing precision
If standard HPLC purification is used, then purification can be achieved, but achieving >99.5% purity requires multiple steps which reduces overall yield
Solution Approach 1:
The patent achieves the dual goal of high purity (>99.5%) and high yield (>70%) by optimizing key parameters: pore size (5-250 Å, preferably 20-150 Å) and functional group concentration (0.1-10 μmol/m²). These parameter optimizations enable single-step purification that simultaneously achieves both high purity and high recovery, eliminating the yield loss associated with multiple sequential purification steps.
Solution Approach 2:
The patent merges multiple purification functions into a single stationary phase by incorporating specific functional groups (carboxyl, sulfonic acid, phosphonic acid, or boronic acid) onto silica particles. This unified stationary phase performs both separation and purification in one step, achieving >99.5% purity with >70% recovery simultaneously, rather than requiring multiple separate purification steps that would cumulatively reduce yield.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified silica particles enable improved separation characteristics, allowing for high-purity purification of GLP-1 and GLP-2 analogs in fewer steps with increased recovery rates, meeting pharmaceutical industry standards of >99.5% purity and <0.1% impurity, while maintaining commercially acceptable yields.
Implementation Method 1
Each component of the mixture to be separated interacts slightly different with the adsorbent material usually due to more or less pronounced physical-chemical interaction of the components with the absorbent material's surface and/or the pore size of the absorbent material.
Data Source
AI summary
Silica particles have a fine pore size of 1 to 250 Angstrom (Å) and comprise a silane group which comprises two groups which are each independently chosen from alkyl, aryl, alkylaryl, heteroalkyl, heteroaryl, and heteroalkylaryl groups. The silica particles are prepared by a method. The silica particles can be used as a stationary phase for purifying a modified conjugated peptide, such as a GLP-1 agonist or a GLP-2 analog.